United States - English - NLM (National Library of Medicine)

ferndale laboratories, inc. - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone acetate 25 mg in 1 g

United States - English - NLM (National Library of Medicine)

sebela pharmaceuticals inc. - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj), pramoxine hydrochloride (unii: 88ayb867l5) (pramoxine - unii:068x84e056) - hydrocortisone acetate 25 mg in 1 ml - indications and usage: topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. contraindications: topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

sebela pharmaceuticals inc. - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj), pramoxine hydrochloride (unii: 88ayb867l5) (pramoxine - unii:068x84e056) - hydrocortisone acetate 25 mg in 1 ml - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

avion pharmaceuticals, llc - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone acetate 20 mg in 1 g

United States - English - NLM (National Library of Medicine)

alaven pharmaceutical llc - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone acetate 100 mg in 10 g

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - lidocaine hydrochloride 30 mg in 1 g - product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution on patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. these products are contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindica

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - lidocaine hydrochloride anhydrous 30 mg in 1 g - product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution on patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. these products are contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pregnancy category c. reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. there are, however, no adequate and well-controlled studies in pregnant women. animal reproduction studies are not always predictive of human response. general consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. the more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. there are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. safety and efficacy in children have not been established.

United States - English - NLM (National Library of Medicine)

rochester pharmaceuticals - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj), pramoxine hydrochloride (unii: 88ayb867l5) (pramoxine - unii:068x84e056) - hydrocortisone acetate 10 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pediatric patients may demonstrate greater susceptibility to topical corticosteroid induced hpa axis suppression and cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.  hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.  administration of topical corticosteroids to children should

United States - English - NLM (National Library of Medicine)

novum pharma, llc - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj), pramoxine hydrochloride (unii: 88ayb867l5) (pramoxine - unii:068x84e056) - hydrocortisone acetate 20 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution on patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. this product is contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pregnancy category c. reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. there are, however, no adequate and well-controlled studies in pregnant women. animal reproduction studies are not always predictive of human response. general consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. the more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. there are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. safety and efficacy in children have not been established.